Rockwell Medical (RMTI) Earnings Analysis
Rockwell Medical (RMTI) next reports earnings on 2026-08-13, consensus EPS -0.235 USD. Last quarter (2026-05-07) it missed with EPS -0.4 USD vs -0.1 USD est (-300%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -4.33.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RMTI next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.235 USD |
| Revenue estimate | 0.02B |
RMTI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.4 USD | -0.1 USD | -300% | Miss |
| 2026-03-26 | -0.1 USD | 0.4 USD | -125% | Miss |
| 2025-08-14 | -0.05 USD | -0.05 USD | 0% | Beat |
| 2025-05-12 | -0.04 USD | -0.3 USD | +86.7% | Beat |
| 2025-03-20 | -0.02 USD | 0.02 USD | -200% | Miss |
| 2024-11-11 | 0.5 USD | 0.1 USD | +400% | Beat |
| 2024-08-12 | 0.01 USD | -0.3 USD | +103.3% | Beat |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
RMTI valuation and analyst view
| Trailing P/E | -4.33 |
|---|---|
| Trailing EPS | -1.37094 USD |
| Price / book | 0.71 |
| Dividend yield | 0.00% |
| Market cap | 0.03B |
| Analyst consensus | Buy (10 buy / 2 hold / 4 sell) |
| Avg price target | 11 USD |
Related research pages
Frequently asked questions
When is Rockwell Medical (RMTI)'s next earnings date?
Rockwell Medical is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.235 USD and revenue estimate of 0.02B.
Did RMTI beat earnings last quarter?
In its 2026-05-07 report, RMTI posted EPS of -0.4 USD versus a -0.1 USD estimate — a miss of 300%.
What is RMTI's earnings track record?
Over the last 7 reported quarters with consensus data, RMTI beat estimates 4 times (57%).
What is RMTI's current P/E ratio and EPS?
RMTI trades at a trailing P/E of -4.33 on trailing EPS of -1.3709368491284506 USD.
What do analysts rate RMTI?
Analyst consensus is "Buy" across 16 ratings (0 strong buy, 10 buy, 2 hold, 4 sell, 0 strong sell). Average 12-month price target: 11 USD.